How long are people on Wegovy, and what does the evidence say?

What the STEP 1 trial showed about stopping versus continuing

The STEP 1 trial, published in the New England Journal of Medicine, ran for 68 weeks. Participants taking semaglutide 2.4mg lost around 15% of their body weight on average. That figure has become the benchmark most people quote.

What gets less attention is what happened next. A withdrawal study that followed STEP 1 participants for a further year found that those who stopped semaglutide regained most of the weight they had lost, while those who continued did not. That is not a sales pitch; it is a pharmacological reality. Semaglutide acts on GLP-1 receptors to suppress appetite and slow gastric emptying. When the medicine stops, so does that effect.

This evidence directly shapes how clinicians think about duration. Weight management with semaglutide is increasingly treated like management of any other chronic condition: you do not take six months of blood-pressure medication and assume your blood pressure is permanently fixed. The question of how long a person stays on Wegovy is really a question about ongoing clinical need, and that is a conversation between the individual and their prescriber, reviewed regularly.

For context on how quickly the medicine starts working, our page on how long Wegovy takes to work covers the early-weeks evidence in more detail.

What NICE's guidance says about the two-year recommendation

NICE's technology appraisal TA875 recommends semaglutide for weight management for up to two years, within a specialist weight management service offering multidisciplinary support. This is not the same as saying two years is always the right duration, it is the maximum covered by the NHS recommendation, reflecting the length of the trials that underpinned the appraisal.

The guidance also includes a stopping criterion: if a patient has not lost at least 5% of their body weight after six months at the maintenance dose, continuing the medicine should be reviewed. That 5% threshold matters because semaglutide does not work equally well for everyone, and prescribers are expected to apply that checkpoint rather than renewing indefinitely.

Private prescribing through a regulated service like nume follows the same clinical principles. A prescriber reviews suitability before every repeat, there is no auto-renewal, and dose increases require fresh clinical evidence. People considering the cost implications of a longer course sometimes find our overview of Wegovy weight loss options online a useful starting point before booking a consultation.

The ethnic-background BMI thresholds that shape NICE eligibility (2.5 kg/m² lower for several backgrounds under UK guidance) apply here too, though duration criteria are the same once treatment has started.

How long do most people actually stay on treatment in practice?

Outside of trial conditions, duration is harder to pin down precisely. What prescribers observe is broadly consistent with the trial story: people who respond well and tolerate the medicine tend to continue; those who do not hit the clinical response markers, or who experience side effects they cannot manage, tend to stop sooner.

The most common reason for a planned stop at a fixed date in the NHS setting is the two-year ceiling in TA875. Private patients, reviewed individually, may continue longer if clinical benefit persists and the prescriber is satisfied. The NHS England guidance on weight-management injections makes clear that wraparound diet and activity support is expected throughout, the medicine is one component, not the whole plan.

Some practical realities shape real-world duration too. Holidays, illness, or simply a week when the delivery clashed with an awkward Monday can all interrupt a course. That is normal and manageable, but it is worth planning ahead with your prescriber rather than improvising a break. For more on what the pace of loss looks like while you are on treatment, our page on how fast people lose weight on Wegovy covers the trajectory evidence week by week.

People sometimes ask whether switching to a different medicine is an option if results plateau. That is a clinical conversation rather than a self-directed decision; our weight-loss treatment overview sets out what is licensed in the UK alongside Wegovy if you want to explore the landscape before your consultation.

Stopping Wegovy: what the evidence says you should expect

Stopping semaglutide is not medically dangerous in the way that stopping some medicines abruptly can be. There is no washout procedure that requires hospitalisation. What the evidence does show, consistently, is that appetite returns and weight tends to follow, gradually, over weeks to months.

This is not a failure of willpower. GLP-1 receptor agonists work by modifying signalling pathways that drive hunger; when the medicine is withdrawn, those pathways revert. For many people, this means that a decision to stop Wegovy is also a decision to restart the weight-management work that the medicine was supporting.

The clinical implication is that prescribers generally want a plan before a patient stops, not after. If you are thinking about your own timeline, or wondering what how long people take Wegovy looks like across different circumstances, our frequently asked questions cover the most common duration questions, and our clinical team reviews every consultation with that long-term picture in mind. You can also read more about how long people stay on Wegovy when treatment is going well.